EU drug regulator’s CHMP backed marketing authorization for Corcept’s Lifyorli (relacorilant) with nab-paclitaxel in platinum-resistant ovarian cancer.
The recommendation cited Phase 2 and Phase 3 ROSELLA data showing longer progression-free survival and overall survival versus nab-paclitaxel alone.
CORT•
